11,532 reports of this reaction
10.9% of all PIMAVANSERIN TARTRATE reports
#1 most reported adverse reaction
HALLUCINATION is the #1 most commonly reported adverse reaction for PIMAVANSERIN TARTRATE, manufactured by Acadia Pharmaceuticals Inc.. There are 11,532 FDA adverse event reports linking PIMAVANSERIN TARTRATE to HALLUCINATION. This represents approximately 10.9% of all 106,130 adverse event reports for this drug.
PIMAVANSERIN TARTRATE has an overall safety score of 85 out of 100. Patients taking PIMAVANSERIN TARTRATE who experience hallucination should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION is a frequently reported adverse event for PIMAVANSERIN TARTRATE, accounting for a significant proportion of all reports.
In addition to hallucination, the following adverse reactions have been reported for PIMAVANSERIN TARTRATE:
The following drugs have also been linked to hallucination in FDA adverse event reports:
HALLUCINATION has been reported as an adverse event in 11,532 FDA reports for PIMAVANSERIN TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION accounts for approximately 10.9% of all adverse event reports for PIMAVANSERIN TARTRATE, making it one of the most commonly reported side effect.
If you experience hallucination while taking PIMAVANSERIN TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.